Obstacles to the development of a safe and effective attenuated pre-erythrocytic stage malaria vaccine.
Attenuated pre-erythrocytic stage malaria vaccines protect humans from sporozoite challenge. Current technology limits the feasibility of their commercial scale production and poses a significant risk of contamination with transmissible agents. Overcoming these barriers will be very challenging. In contrast, subunit vaccines appear quite feasible and show great promise as candidate malaria vaccines.
Ripley Ballou
W
W
Worldwide Clinical Development, GlaxoSmithKline Biologicals, Rue de l'Institut 89, 1330 Rixensart, Belgium. ripley.ballou@gskbio.com
D000818:Animals; D015195:Drug Design; D006801:Humans; D008288:Malaria / Q000517:prevention & control*; D017780:Malaria Vaccines / Q000737:chemistry / Q000276:immunology; D010961:Plasmodium / Q000502:physiology; D015800:Protozoan Proteins / Q000737:chemistry / Q000276:immunology; D034101:Sporozoites / Q000276:immunology; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic / Q000737:chemistry / Q000276:immunology
D017780:Malaria Vaccines; D015800:Protozoan Proteins; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic